Heteromodifikation des TRAIL-Trimers für eine verbesserte Arzneimittelabgabe und In-vivo-Antitumoraktivitäten
Li-Qiang Pan, Wen-Bin Zhao, Jun Lai, Ding Ding, Xiao-Yue Wei, Yang-Yang Li, Wen-Hui Liu, Xiao-Yue Yang , Ying-Chun Xu, Shu-Qing Chen
Zusammenfassung
Poor pharmacokinetics and resistance within some tumor cell lines have been the major obstacles during the preclinical or clinical application of TRAIL (tumor-necrosis-factor (TNF)-related apoptosis-inducing ligand). The half-life of TRAIL114-281 (114 to 281 amino acids) was revealed to be no more than 30 minutes across species. Therefore maleimido activated PEG (polyethylene glycol) and MMAE (Monomethyl Auristatin E) were applied to site-specifically conjugate with the mutated cysteines from different monomers of TRAIL successively, taking advantage of steric effects involved within TRAIL mutant conjugations. As a result, TRAIL trimer was hetero-modified for different purposes. And the resulting PEG-TRAIL-vcMMAE conjugate exhibited dramatically improved half-life (11.54 h), favourable in vivo targeting capability and antitumor activities while no sign of toxicity in xenograft models, suggesting it's a viable therapeutic and drug delivery strategy.
Related products
Abbreviation: mPEG-MAL
Name: Methoxypoly(ethylene glycol) maleimide
For more product information, please contact us at:
US Tel: 1-844-782-5734
US Tel: 1-844-QUAL-PEG
CHN Tel: 400-918-9898
Email: sales@sinopeg.com
